References Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (transcend-T2D-1): A double-blind, randomised, phase 3 trial - the Lancet
Conclusion & Next Steps For patients in Connecticut researching retatrutide in Connecticut, semaglutide, tirzepatide, or related peptide therapy, the most important takeaway is that muscle preservation should be part of the treatment conversation from the beginning
They looked at 21 major trials involving nearly 100,000 patients
The nurse initially kickstarted her wellness journey after giving birth to her two daughters, looking for solutions to shed the extra pounds she gained during pregnancy
Age and Health Status Coverage is standard for adults aged 18 and older